Bio-X


Showing 21-40 of 1,154 Results

  • Michael Angelo

    Michael Angelo

    Associate Professor of Pathology

    BioMichael Angelo, MD PhD is a board-certified pathologist and assistant professor in the department of Pathology at Stanford University School of Medicine. Dr. Angelo is a leader in high dimensional imaging with expertise in tissue homeostasis, tumor immunology, and infectious disease. His lab has pioneered the construction and development of Multiplexed Ion Beam Imaging by time of flight (MIBI-TOF). MIBI-TOF uses secondary ion mass spectrometry and metal-tagged antibodies to achieve rapid, simultaneous imaging of dozens of proteins at subcellular resolution. In recognition of this achievement, Dr. Angelo received the NIH Director’s Early Independence award in 2014. His lab has since used this novel technology to discover previously unknown rule sets governing the spatial organization and cellular composition of immune, stromal, and tumor cells within the tumor microenvironment in triple negative breast cancer. These findings were found to be predictive of single cell expression of several immunotherapy drug targets and of 10-year overall survival. This effort has led to ongoing work aimed at elucidating structural mechanisms in the TME that promote recruitment of cancer associated fibroblasts, tumor associated macrophages, and extracellular matrix remodeling. Dr. Angelo is the recipient of the 2020 DOD Era of Hope Award and a principal investigator on multiple extramural awards from the National Cancer Institute, Breast Cancer Research Foundation, Parker Institute for Cancer Immunotherapy, the Bill and Melinda Gates Foundation, and the Human Biomolecular Atlas (HuBMAP) initiative.

  • Martin S. Angst

    Martin S. Angst

    Professor of Anesthesiology, Perioperative and Pain Medicine (MSD)

    Current Research and Scholarly InterestsOur laboratory studies biological and clinical determinants of human resilience using surgery as an injury model.

  • Justin P. Annes M.D., Ph.D.

    Justin P. Annes M.D., Ph.D.

    Associate Professor of Medicine (Endocrinology)

    Current Research and Scholarly InterestsThe ANNES LABORATORY of Molecular Endocrinology: Leveraging Chemical Biology to Treat Endocrine Disorders

    DIABETES
    The prevalence of diabetes is increasing at a staggering rate. By the year 2050 an astounding 25% of Americans will be diabetic. The goal of my research is to uncover therapeutic strategies to stymie the ensuing diabetes epidemic. To achieve this goal we have developed a variety of innovate experimental approaches to uncover novel approaches to curing diabetes.

    (1) Beta-Cell Regeneration: Diabetes results from either an absolute or relative deficiency in insulin production. Our therapeutic strategy is to stimulate the regeneration of insulin-producing beta-cells to enhance an individual’s insulin secretion capacity. We have developed a unique high-throughput chemical screening platform which we use to identify small molecules that promote beta-cell growth. This work has led to the identification of key molecular pathways (therapeutic targets) and candidate drugs that promote the growth and regeneration of islet beta-cells. Our goal is to utilize these discoveries to treat and prevent diabetes.

    (2) The Metabolic Syndrome: A major cause of the diabetes epidemic is the rise in obesity which leads to a cluster of diabetes- and cardiovascular disease-related metabolic abnormalities that shorten life expectancy. These physiologic aberrations are collectively termed the Metabolic Syndrome (MS). My laboratory has developed an original in vivo screening platform t to identify novel hormones that influence the behaviors (excess caloric consumption, deficient exercise and disrupted sleep-wake cycles) and the metabolic abnormalities caused by obesity. We aim to manipulate these hormone levels to prevent the development and detrimental consequences of the MS.

    HEREDIATY PARAGAGLIOMA SYNDROME
    The Hereditary Paraganglioma Syndrome (hPGL) is a rare genetic cancer syndrome that is most commonly caused by a defect in mitochondrial metabolism. Our goal is to understand how altered cellular metabolism leads to the development of cancer. Although hPGL is uncommon, it serves as an excellent model for the abnormal metabolic behavior displayed by nearly all cancers. Our goal is to develop novel therapeutic strategies that target the abnormal behavior of cancer cells. In the laboratory we have developed hPGL mouse models and use high throughput chemical screening to identify the therapeutic susceptibilities that result from the abnormal metabolic behavior of cancer cells.

    As a physician scientist trained in clinical genetics I have developed expertise in hereditary endocrine disorders and devoted my efforts to treating families affected by the hPGL syndrome. By leveraging our laboratory expertise in the hPGL syndrome, our care for individuals who have inherited the hPGL syndrome is at the forefront of medicine. Our goal is to translate our laboratory discoveries to the treatment of affected families.

  • Eric Appel

    Eric Appel

    Associate Professor of Materials Science and Engineering, Senior Fellow at the Woods Institute for the Environment and Associate Professor, by courtesy, of Pediatrics (Endocrinology) and of Bioengineering

    Current Research and Scholarly InterestsThe underlying theme of the Appel Lab at Stanford University integrates concepts and approaches from supramolecular chemistry, natural/synthetic materials, and biology. We aim to develop supramolecular biomaterials that exploit a diverse design toolbox and take advantage of the beautiful synergism between physical properties, aesthetics, and low energy consumption typical of natural systems. Our vision is to use these materials to solve fundamental biological questions and to engineer advanced healthcare solutions.

  • Amin Arbabian

    Amin Arbabian

    Professor of Electrical Engineering

    Current Research and Scholarly InterestsMy group's research covers RF circuits and system design for (1) biomedical, (2) sensing, and (3) Internet of Things (IoT) applications.

  • Ronald L. Ariagno

    Ronald L. Ariagno

    Professor (Clinical) of Pediatrics, Emeritus

    Current Research and Scholarly InterestsDevelopmental Physiology and Sudden Infant Death Syndrome Research Laboratory closed in 2008.

    Current effort, as Chair of Task Force and neonatal consult at the FDA, is to establish through consensus a culture of investigation and collaboration for all clinical neonatology practices: academic, corporate and community based to maximize the opportunity to participate in research effort needed for the regulatory approval of neonatal therapeutics to improve the outcome of critically ill infants.

  • Kevin Arrigo

    Kevin Arrigo

    Donald and Donald M. Steel Professor of Earth Sciences and Senior Fellow at the Woods Institute for the Environment

    Current Research and Scholarly InterestsInvestigates role of ocean biology in gobal carbon and nutrient cycles.

  • Steven Artandi, MD, PhD

    Steven Artandi, MD, PhD

    Laurie Kraus Lacob Director of the Stanford Cancer Institute (SCI), Jerome and Daisy Low Gilbert Professor and Professor of Biochemistry

    Current Research and Scholarly InterestsTelomeres are nucleoprotein complexes that protect chromosome ends and shorten with cell division and aging. We are interested in how telomere shortening influences cancer, stem cell function, aging and human disease. Telomerase is a reverse transcriptase that synthesizes telomere repeats and is expressed in stem cells and in cancer. We have found that telomerase also regulates stem cells and we are pursuing the function of telomerase through diverse genetic and biochemical approaches.

  • Ann M. Arvin

    Ann M. Arvin

    Lucile Salter Packard Professor of Pediatrics and Professor of Microbiology and Immunology, Emerita

    Current Research and Scholarly InterestsOur laboratory investigates the pathogenesis of varicella zoster virus (VZV) infection, focusing on the functional roles of particular viral gene products in pathogenesis and virus-cell interactions in differentiated human cells in humans and in Scid-hu mouse models of VZV cell tropisms in vivo, and the immunobiology of VZV infections.

  • Euan A. Ashley

    Euan A. Ashley

    Roger and Joelle Burnell Professor of Genomics and Precision Health, Arthur L. Bloomfield Professor of Medicine and Professor of Genetics, of Biomedical Data Science and, by courtesy, of Pathology

    Current Research and Scholarly InterestsThe Ashley lab is focused on precision medicine. We develop methods for the interpretation of whole genome sequencing data to improve the diagnosis of genetic disease and to personalize the practice of medicine. At the wet bench, we take advantage of cell systems, transgenic models and microsurgical models of disease to prove causality in biological pathways and find targets for therapeutic development.

  • Laura Attardi

    Laura Attardi

    Catharine and Howard Avery Professor of the School of Medicine and Professor of Genetics

    Current Research and Scholarly InterestsOur research is aimed at defining the pathways of p53-mediated apoptosis and tumor suppression, using a combination of biochemical, cell biological, and mouse genetic approaches. Our strategy is to start by generating hypotheses about p53 mechanisms of action using primary mouse embryo fibroblasts (MEFs), and then to test them using gene targeting technology in the mouse.

  • Jeffrey Axelrod

    Jeffrey Axelrod

    Professor of Pathology

    Current Research and Scholarly InterestsGenetic and cell biological analyses of signals controlling cell polarity and morphogenesis. Frizzled signaling and cytoskeletal organization.

  • Rosa Bacchetta

    Rosa Bacchetta

    Professor (Research) of Pediatrics (Stem Cell Transplantation)

    Current Research and Scholarly InterestsIn the coming years, I plan to further determine the genetic and immunological basis of diseases with autoimmunity or immune dysregulation in children. I believe that much can still be learned from the in depth mechanistic studies of pediatric autoimmune diseases. Genomic analysis of the patients' samples has become possible which may provide a rapid indication of altered target molecules. I plan to implement robust functional studies to define the consequences of these genetic abnormalities and bridge them to the patient's clinical phenotype.

    Understanding functional consequences of gene mutations in single case/family first and then validating the molecular and cellular defects in other patients with similar phenotypes, will anticipate and complement cellular and gene therapy strategies.

    For further information please visit the Bacchetta Lab website:
    http://med.stanford.edu/bacchettalab.html

  • Stephen A. Baccus

    Stephen A. Baccus

    Professor of Neurobiology

    Current Research and Scholarly InterestsWe study how the neural circuitry of the vertebrate retina encodes visual information and performs computations. To control and measure the retinal circuit, we present visual images while performing simultaneous two-photon imaging and multielectrode recording. We perturb the circuit as it operates using simultaneous intracellular current injection and multielectrode recording, and use the resulting large data sets to construct models of retinal computation.

  • Jeremy Bailenson

    Jeremy Bailenson

    Thomas More Storke Professor, Senior Fellow at the Woods Institute for the Environment and Professor, by courtesy, of Education

    BioJeremy Bailenson is founding director of Stanford University’s Virtual Human Interaction Lab, Thomas More Storke Professor in the Department of Communication, Professor (by courtesy) of Education, Professor (by courtesy) Program in Symbolic Systems, and a Senior Fellow at the Woods Institute for the Environment. He has served as Director of Graduate Studies in the Department of Communication for fifteen years. He earned a B.A. from the University of Michigan in 1994 and a Ph.D. in cognitive psychology from Northwestern University in 1999. He spent four years at the University of California, Santa Barbara as a Post-Doctoral Fellow and then an Assistant Research Professor.

    Bailenson studies the psychology of Virtual and Augmented Reality, in particular how virtual experiences lead to changes in perceptions of self and others. His lab builds and studies systems that allow people to meet in virtual space, and explores the changes in the nature of social interaction. His most recent research focuses on how virtual experiences can transform education, environmental conservation, empathy, and health. He is the recipient of the Dean’s Award for Distinguished Teaching at Stanford. In 2020, IEEE recognized his work with “The Virtual/Augmented Reality Technical Achievement Award”.

    He has published more than 250 academic papers, spanning the fields of communication, computer science, education, environmental science, law, linguistics, marketing, medicine, political science, and psychology. His work has been continuously funded by the National Science Foundation for over 25 years.

    His first book Infinite Reality, co-authored with Jim Blascovich, emerged as an Amazon Best-seller eight years after its initial publication, and was quoted by the U.S. Supreme Court. His new book, Experience on Demand, was reviewed by The New York Times, The Wall Street Journal, The Washington Post, Nature, and The Times of London, and was an Amazon Best-seller.

    He has written opinion pieces for The Washington Post, The Wall Street Journal, Harvard Business Review, CNN, PBS NewsHour, Wired, National Geographic, Slate, The San Francisco Chronicle, TechCrunch, and The Chronicle of Higher Education, and has produced or directed six Virtual Reality documentary experiences which were official selections at the Tribeca Film Festival. His lab has exhibited VR in hundreds of venues ranging from The Smithsonian to The Superbowl.

  • Michael Baiocchi

    Michael Baiocchi

    Associate Professor of Epidemiology and Population Health and, by courtesy, of Statistics and of Medicine (Stanford Prevention Research Center)
    On Partial Leave from 01/01/2026 To 12/01/2026

    BioProfessor Baiocchi is a PhD statistician in Stanford University's Epidemiology and Population Health Department. He thinks a lot about behavioral interventions and how to rigorously evaluate if and how they work. Methodologically, his work focuses on creating statistically rigorous methods for causal inference that are transparent and easy to critique. He designed -- and was the principle investigator for -- two large randomized studies of interventions to prevent sexual assault in the settlements of Nairobi, Kenya.

    Professor Baiocchi is an interventional statistician (i.e., grounded in both the creation and evaluation of interventions). The unifying idea in his research is that he brings rigorous, quantitative approaches to bear upon messy, real-world questions to better people's lives.

  • Julie Baker

    Julie Baker

    Professor of Genetics

    Current Research and Scholarly InterestsWe examine how cells communicate and function during fetal development. The work in my laboratory focuses on the establishment of specific cell fates using genomics to decipher interactions between chromatin and developmental signaling cascades, between genomes and rapidly evolving cell types, and between genomic copy number variation and gene expression. In recent years we have focused on the vastly understudied biology of the trophoblast lineage, particularly how this lineage evolved.

  • Karthik Balakrishnan, MD, MPH, FAAP, FACS

    Karthik Balakrishnan, MD, MPH, FAAP, FACS

    Professor of Otolaryngology - Head & Neck Surgery (OHNS) and, by courtesy, of Pediatrics

    Current Research and Scholarly InterestsDr. Balakrishnan's research focuses on innovative ways to improve and standardize treatments and measure outcomes in complex pediatric airway and aerodigestive conditions , as well as ways to reduce treatment costs and medical errors. By improving outcomes and reducing costs, he aims to improve the value of care, while also optimizing patient and caregiver experience during the care process.